Non-small-cell lung carcinoma (NSCLC) is among the deadliest of human cancers. The CDKN2A locus, which houses the INK4a and ARF tumor suppressor genes, is frequently altered in NSCLC. However, the specific role of ARF in pulmonary tumorigenesis remains unclear. KRAS and other oncogenes induce the expression of ARF, thus stabilizing p53 activity and arresting cell proliferation. To address the role of ARF in Kras-driven NSCLC, we compared the susceptibility of NIH/Ola strain wild-type and Arf-knockout mice to urethane-induced lung carcinogenesis. Lung tumor size, malignancy and associated morbidity were significantly increased in Arf À / À compared with Arf þ / þ animals at 25 weeks after induction. Pulmonary tumors from Arf-knockout mice exhibited increased cell proliferation and DNA damage compared with wild-type mice. A subgroup of tumors in Arf À / À animals presented as dedifferentiated and metastatic, with many characteristics of pulmonary sarcomatoid carcinoma, a neoplasm previously undocumented in mouse models. Our finding of a role for ARF in NSCLC is consistent with the observation that benign adenomas from Arf þ / þ mice robustly expressed ARF, while ARF expression was markedly reduced in malignant adenocarcinomas. ARF expression also frequently colocalized with the expression of p21 CIP1 , a transcriptional target of p53, arguing that ARF induces the p53 checkpoint to arrest cell proliferation in vivo. Taken together, these findings demonstrate that induction of ARF is an early response in lung tumorigenesis that mounts a strong barrier against tumor growth and malignant progression. 
INTRODUCTION
Non-small-cell lung carcinoma (NSCLC) is the leading cause of cancer-related death in the United States and the world, with a 5-year relative survival rate of only 17%. 1 Lung adenocarcinoma, the predominant histological subtype of NSCLC, commonly harbors genetic alterations in KRAS (38%), CDKN2A (15%) and TP53 (36%). 2 However, the timing, impact and clinical significance of these changes are not yet fully understood.
The CDKN2A locus houses both the ARF (p14 ARF in humans, p19
Arf in mice) and INK4a (p16 INK4a ) tumor suppressor genes. ARF, so named because it is transcribed from an alternate reading frame, shares no homology with INK4a and is controlled by a separate promoter. 3 Both proteins induce cell cycle arrest, albeit by regulating different signaling pathways. Under conditions of cellular stress, INK4a promotes G1 arrest by inhibiting cyclin D-CDK4/6 complexes and preventing hyperphosphorylation of the RB protein. 4 In contrast, ARF triggers arrest at the G1 and G2 checkpoints, 3 in part by antagonizing the MDM2 ubiquitin ligase and stabilizing cellular p53 levels. 4 Although p53-independent tumor suppression by ARF has been demonstrated, 5 these activities are not as well elucidated as the canonical ARF-MDM2-p53 signaling axis.
Several recent studies examining tumor suppression by ARF in NSCLC have yielded different results in different contexts. While ARF expression was found to be elevated in premalignant lung lesions in Kras G12V animals, 6 the expression of ARF was primarily restricted to high-grade adenocarcinomas in two mouse models of Kras
G12D
-driven lung cancer. 7, 8 In addition, Arf loss had only a modest impact on lung tumor growth or progression in Kras G12D knock-in animals. 9 These latter results are noteworthy, given the established relationship between RAS, ARF and p53 5 and the observation that Trp53 loss of function markedly enhanced the growth and malignant progression of Kras-driven lung tumors. 10, 11 Moreover, loss of ARF expression has been observed in lung tumors in mice 12 and in humans, [13] [14] [15] and restoration of ARF expression arrests the growth of patient-derived lung cancer cell lines. 16, 17 As ARF status may have important implications for NSCLC patient prognosis and clinical management, further examination of the role of ARF in lung tumorigenesis is warranted. Herein, we identify ARF as a major suppressor of the growth and malignant progression of carcinogen-induced, Krasdriven NSCLC.
RESULTS
Arf deficiency leads to increased lung tumor size and associated morbidity To examine the role of ARF in lung tumorigenesis, we injected cohorts of Arf þ / þ , Arf þ / À and Arf À / À mice with the pulmonary carcinogen urethane. Kaplan-Meier analyses indicated that urethane-exposed Arf À / À animals experienced significantly shortened overall survival (Supplementary Figure 1a) and increased lung tumor-associated morbidity ( Figure 1a ) compared with their Arf þ / þ , Arf þ / À and unexposed Arf À / À littermates (log-rank test for trend, Po0.0001). By 25 weeks after injection, 68.2% of Arf mice exposed to urethane succumbed to lung tumors, whereas all Arf þ / þ , Arf þ / À and unexposed Arf À / À mice remained viable ( Figure 1a) . Arf À / À mice also presented with lymphomas and sarcomas (data not shown) at a rate consistent with prior reports. 18 As described previously, two-thirds of Arf À / À animals also developed hepatic vascular lesions after urethane exposure. 19 These lesions were typically small and had a limited impact on overall survival.
At necropsy, Arf À / À animals presented with substantial pulmonary tumor burden (Figure 1b) . Consistent with previous urethane carcinogenesis studies, 20 all exposed animals developed at least one lung tumor nodule. However, although tumor multiplicity did not vary between genotypes (Figure 1c) , tumor size was greatly increased in Arf À / À compared with Arf þ / þ mice (Po0.0001; Figure 1d ). Notably, while Arf þ / þ and Arf þ / À mice rarely developed tumors exceeding 3 mm in diameter, Arf À / À mice routinely developed tumors between 4 and 17 mm diameter (Supplementary Figure 1b) . This marked increase in tumor size corresponded with a nearly threefold increase in lung mass in Arf À / À mice ( Figure 1e ). In summary, while homozygous loss of Arf did not affect lung tumor initiation after carcinogen exposure, it greatly increased the rate of lung tumor growth and associated morbidity and mortality.
Loss of Arf accelerates tumor invasion and metastasis The urethane model of mouse lung carcinogenesis captures a tumor development spectrum that proceeds from hyperplasia to benign adenomas and, infrequently, to malignant adenocarcinomas. 21 At 25 weeks after urethane, the majority of tumors present in Arf þ / þ (65.9%) and Arf þ / À (72.5%) animals were identified as pulmonary adenomas (Figure 1f (top) and g). The incidence of adenocarcinomas was greatly increased (79.5%) in Arf À / À animals (Po0.0001; Figure 1g ). These pulmonary adenocarcinomas were characterized by pleomorphic nuclei, abundant mitotic activity and invasion into adjacent parenchyma and airways (Figure 1f , bottom). Intravasation of adenocarcinoma cells was also observed (Figure 1h) .
A subset of adenocarcinomas in Arf À / À mice exhibited exceptionally poor differentiation (Figures 2a and b ) and metastasized to both intra- (Figure 2d , bottom) and extra-thoracic sites (Figures 2c and e). These tumors displayed histopathological characteristics typical of pulmonary sarcomatoid carcinoma, 22 an aggressive tumor type that, to our knowledge, has not previously been observed in mice. Although the metastatic lesions most closely resembled undifferentiated spindle cell tumors, regions of the metastases that retained epithelial differentiation expressed prosurfactant protein C (Figure 2d ), consistent with lung epithelial origin. Immunohistochemistry further illustrated that the mesenchymal marker vimentin was absent from the epithelioid compartments, but stained strongly in the spindle regions of the metastatic lesions (Figure 2e ). Cytokeratin 8, a marker of epithelium, was expressed in both cell compartments. In summary, the sarcomatoid metastases exhibited a mixture of mesenchymal and epithelial markers. These unusual pulmonary tumors were never observed in Arf þ / þ or Arf þ / À animals, but were found in 50% of Arf À / À mice examined (Table 1 ; n ¼ 10, each genotype). Coincidental metastases to neighboring lymph nodes, the chest wall or the peritoneal cavity were similarly identified in 40-50% of Arf-deficient animals. Figure 2) . The hyperproliferative effect of Arf deficiency was accompanied by a substantial increase in DNA damage. Marked elevation in the expression of phosphorylated histone H2A.X, a sensitive indicator of DNA damage, was observed in both Arf À / À adenomas and adenocarcinomas compared with wild type (Figure 3b) . Notably, however, the apoptotic marker cleaved caspase-3 was largely undetectable at all stages of tumor development in both genotypes (Supplementary Figure 3) , suggesting that apoptosis has little role in suppressing urethane-induced lung carcinogenesis.
To elucidate the antiproliferative properties of ARF, we examined mitogenic signaling in wild-type and Arf-deficient lung tumors.
Consistent with prior reports on urethane carcinogenesis, Figures 4b and c) , a pattern linked to mitogenic stimulation and cell cycle entry. 24 KRAS-ERK pathway signaling promotes the expression of cyclin D1, an important component of the cell cycle machinery that is essential for transformation by oncogenic RAS. 25, 26 Immunoblot analysis of cyclin D1 expression revealed upregulation of the cyclin D1 protein in adenomas and adenocarcinomas from Arf À / À compared with Arf þ / þ mice ( Figure 3C ). Similar to our observations of phospho-ERK1/2 localization, the gains in cyclin D1 expression were largely restricted to the nuclear compartment (Figure 3d ). Quantitative real-timepolymerase chain reaction (qPCR) analysis found no significant difference in the expression of Ccnd1 transcript between adenocarcinomas harvested from Arf À / À and Arf þ / þ mice (Figure 3e ), implying that the misregulation occurs post-transcriptionally.
Early induction of ARF by mutant KRAS activates a p53-dependent antiproliferative response Many of the tumor-suppressive properties previously ascribed to ARF are linked to its role in stabilizing p53 levels in cells stressed by oncogenic RAS. 5, 27 Having found that homozygous Arf loss facilitates urethane carcinogenesis, we hypothesized that ARF may act as an in vivo barrier to Kras-driven lung tumor growth and progression. We therefore examined ARF expression in lung tumors from wild-type mice. Early-stage adenomas exhibited prominent ARF expression (Figure 4a, top) , whereas the expression of ARF in adenocarcinomas was restricted to small, sporadic foci (Figure 4a Figure 5a) . ARF expression was thus triggered early and silenced late during Kras-driven pulmonary tumorigenesis.
To investigate whether ARF acts through a p53-dependent pathway to suppress tumor development, we examined the expression of the prototypical p53 transcriptional target p21 Figure 5d) , further identified a trend toward decreased expression in Arf-deficient compared with Arf þ / þ tumors. Taken together, these data suggest that the expression of ARF triggers an antiproliferative response through p53 that occurs in the absence of persistent DNA damage signaling.
We attempted to confirm the p53 dependence of pulmonary tumor suppression by ARF by repeating the urethane carcinogenesis study in Trp53 À / À mice. Unfortunately, all animals died from lymphoma by 15 weeks after exposure, precluding analysis of lung tumor development (data not shown). An examination of lung tumors isolated from Arf þ / þ and Arf À / À animals revealed similar low-level expression of p53 protein throughout tumor development (Figure 4d) . Notably, p53 exhibited no phosphorylation on the serine 15 residue, implying that the DNA damage response did not contribute to p53 stabilization (Supplementary Figure 5e) . Genetic analysis of adenocarcinomas from Arf þ / þ and Arf À / À mice found that the Trp53 locus remained intact in both genotypes (Figure 4e ; n ¼ 8 each). However, sequencing of Trp53 Number of mice presenting with X1 indicated lesion (%). A subset of lung samples from urethane-exposed male mice of each genotype was selected at random for scoring. Hematoxylin-and eosin-stained sections were diagnosed blind to genotype. exons 2-11 identified three missense mutations in wild-type adenocarcinomas and one frameshift and two missense mutations in Arf-deficient adenocarcinomas (Supplementary Table 1 ), demonstrating that selection for Trp53 mutation occurs even in the absence of Arf. It is also important to note that we observed continued p21 CIP1 expression in adenocarcinomas from Arf À / À Figure 3 . RAS pathway signaling, cell proliferation and DNA damage. (a) Arf À / À adenocarcinomas (AC) displayed a higher proliferation index than tumors from Arf þ / þ littermates, as shown by phosphorylated histone H3 staining (****Po0.0001; n ¼ 119 adenoma and 220 AC fields counted from Arf þ / þ ; n ¼ 22 adenoma and 829 AC fields from Arf À / À mice). (b) Phosphorylated histone H2A.X staining illustrates a marked increase in DNA damage in tumors from Arf-deficient mice (****Po0.0001; ***P ¼ 0.0001; n ¼ 85 adenoma and 307 AC fields counted from Arf þ / þ ; n ¼ 31 adenoma and 788 AC fields from Arf À / À mice). In addition to H2A.X þ cells occurring more frequently per field, damage foci were also larger and more numerous per cell in Arf À / À mice compared with Arf þ / þ . Note that the paucity of adenomas in Arf À / À animals prevented inclusion of additional fields in the statistical analysis of phospho-H3 and phospho-H2A.X staining. (c) Nuclear cyclin D1 and phospho-ERK1/2 expression were strongly upregulated in adenomas (top) and adenocarcinomas (bottom) from individual Arf-deficient mice (lanes 4-6 and 10-12) compared with Arf þ / þ mice (lanes 1-3 and 7-9). b-actin is provided as loading control. b-tubulin and lamin B1 are included as markers of cytoplasmic and nuclear compartments, respectively. (d) Relative intensities of nuclear versus cytoplasmic cyclin D1 bands from (c) compared between genotypes at each tumor stage. All samples were normalized to b-actin (*P ¼ 0.0114 adenomas; *P ¼ 0.0308 ACs). (e) Expression of Ccnd1 mRNA is equivalent in adenocarcinomas from Arf þ / þ and Arf À / À animals. Gapdh was used as endogenous control. Data are plotted as fold change compared with mean Arf þ / þ value (n ¼ 6 tumors per genotype; P ¼ 0.6600). NS, nonsignificant.
mice, although the pattern of immunoreactivity differed appreciably. In Arf-deficient tumors, unlike in wild-type, p21 expression was closely associated with that of phospho-H2A.X (Supplementary Figure 5b, bottom) . Induction of p21 by DNA damage signaling has been previously demonstrated and can occur in the absence of p53. 28 Regardless of the initiating signal, it is clear that the remnant p21 expression is insufficient to restrain lung tumorigenesis in an Arf-null environment.
DISCUSSION
Herein, we tested the hypothesis that ARF suppresses carcinogeninduced, Kras-driven lung adenocarcinoma. Germline Arf deletion resulted in the development of large, poorly differentiated and metastatic lung tumors. Increased proliferation and DNA damage in tumors from Arf-deficient mice, accompanied by elevated expression of nuclear cyclin D1 and phospho-ERK1/2, indicate that ARF functions to restrain hyperproliferation and maintain genomic integrity in a Kras-mutant lung environment. In wild-type mice, ARF expression was typically confined to benign adenomas and colocalized with p21 CIP1 , suggesting that tumor suppression by ARF is an early response in lung carcinogenesis that proceeds through a p53-dependent pathway.
The CDKN2A locus, which houses both Arf and Ink4a, has been proposed as a candidate for the Papg-1 (that is, pulmonary adenoma progression 1) susceptibility locus in mice. The locus maps to mouse chromosome 4 and was so named because of its significant association with lung tumor size. 29 A previous study investigating this connection used the double-knockout Arf À / À ; Ink4a À / À mouse, precluding direct analysis of the contributions of each gene to pulmonary tumor suppression in vivo. 30 On the basis of strain-specific variation in INK4a function, but not in ARF, the authors deduced that Ink4a is the major lung tumor suppressor gene encoded from Cdkn2a. Indeed, there is strong evidence that Ink4a deficiency contributes to pulmonary tumorigenesis. 17, 31 However, our study clearly demonstrates that Arf loss is sufficient to facilitate the malignant progression of pulmonary neoplasia. Parsing the tumor-suppressive activities of ARF and INK4a has proven difficult, both in mice and humans. Selective inactivation of ARF does occur in human cancers, but silencing of the entire CDKN2A locus is a far more common event. 32 The findings described herein are highly suggestive of an important role for both ARF and INK4a in suppressing lung adenocarcinoma development.
Arf-deficient mice frequently presented with lung tumors that were markedly dedifferentiated and, at times, sarcomatoid in appearance. These latter lesions exhibited many of the characteristics of pulmonary sarcomatoid carcinoma (PSC), a rare neoplasm in humans defined as poorly differentiated NSCLCs containing abundant sarcomatoid or spindle cell elements. 22 These lesions have not previously been described in rodents. 33 PSC is believed to be a 'transitional' tumor type, with the sarcomatoid elements of the lesion deriving from epithelial carcinoma cells through the activation of an epithelial-mesenchymal transition program. 34 The development of PSC lesions in Arf-deficient animals argues that ARF may regulate the in vivo differentiation of cancer cells. In support of this, loss of heterozygosity at chromosome 9p21 (that is, CDKN2A) has been reported in human PSC cases, 35 and Arf-deficiency has been shown to promote epithelial-mesenchymal transition in a breast cancer model. 36 Furthermore, the spindle cell morphology and dual staining of cytokeratin 8 and vimentin observed in these lesions fit the proposed diagnostic criteria for epithelial-mesenchymal transition tumors in the mouse. 37 Additional investigation of the contribution of ARF to the epithelial-mesenchymal transition program in carcinogenesis, as well as the clinical significance of these unusual lesions, is clearly warranted. Our model will provide a unique platform on which to conduct future examinations of PSC pathogenesis.
Our study further revealed that Arf loss engenders the nuclear accumulation of cyclin D1, a crucial regulator of CDK4/6 kinase activity during the G1 phase of the cell cycle. 38 ARF has been shown to inhibit transcription of cyclin D1, 39,40 but we found no difference in mRNA levels of Ccnd1 between Arf þ / þ and Arf À / À tumors, suggesting that the misregulation occurs post-transcriptionally. Although the precise mechanistic link between ARF and cyclin D1 remains to be determined, previous studies have demonstrated that persistent nuclear localization of cyclin D1 promotes DNA re-replication and genomic instability. 41, 42 For this reason, increased nuclear cyclin D1 is a poor prognostic indicator in NSCLC. 43 It is tempting to speculate that the high levels of DNA damage we observed in Arf-deficient animals result from misregulation of cyclin D1, but additional pathways connecting ARF to DNA damage signaling and repair have been proposed. [44] [45] [46] Regardless, as recent works have described, 47, 48 Arf loss may have deleterious consequences for genomic stability.
The timing and functional importance of ARF expression during lung tumorigenesis are likely context dependent. [6] [7] [8] [9] Notably, studies identifying ARF expression as a late event in tumor development were performed in the context of Trp53 nullizygosity. It is perhaps not surprising that regulation of ARF expression is altered in a Trp53-deficient environment, given that p53 represses Arf transcription. 49 Our data clearly demonstrate that, in a pulmonary environment without ab initio alteration of tumor suppressor pathways, induction of ARF expression is an early event in neoplastic development. As benign adenomas progress to malignant adenocarcinomas, ARF protein expression decreases significantly, a finding consistent with the increased incidence of adenocarcinomas in Arf-deficient animals. All told, our results bear many similarities to previously published accounts of lung tumorigenesis in Kras-mutant, p53-deficient animals, including increased lung tumor growth, accelerated malignancy and enhanced metastatic capability. 10, 11, 50 These commonalities strongly suggest that lung tumor suppression by ARF is mediated, at least in part, through p53.
The oncogenic stress response acting through ARF-p53, rather than the short-term DNA damage response, has been proposed as the predominant tumor-suppressive mechanism in vivo. 51, 52 We have previously shown that ARF has both p53-dependent and -independent roles in the suppression of Hras-driven skin carcinogenesis. 53 Our observation that ARF and p21 are frequently coexpressed in lung tumors, without concomitant DNA damage, similarly argues that the ARF-p53 signaling axis is activated by mutant KRAS and arrests pulmonary tumorigenesis. P53 protein was found to be present in both adenomas and adenocarcinomas from Arf þ / þ and Arf À / À mice. However, regulation of p53 activity is an extremely complex process that involves many layers of post-translational modification and protein-protein interaction. 54, 55 These complexities are difficulty to interrogate and were not fully addressed in this study. We also observed that Arf-deficient adenocarcinomas developed Trp53 mutations at a similar frequency as wild-type adenocarcinomas. Interestingly, Trp53 mutations in tumors from Arf þ / þ mice were found exclusively in the DNA-binding domain, whereas the mutations in Arf À / À mice predominantly occurred in the transactivation domain. The significance of this segregation of mutations by genotype, along with the functionality of p53 in Arfdeficient tumors, will be the subject of future investigations. It is worth noting, however, that Arf and Trp53 loss are not necessarily mutually exclusive events in lung tumorigenesis, 14, 15 and that mice with alterations in both Trp53 and Arf exhibit increased lung tumor multiplicity and accelerated progression compared with either alone. 56 It therefore remains possible, and perhaps even probable, that ARF and p53 also have independent tumorsuppressive functions in the lung.
Using the urethane lung carcinogenesis model, we have identified a novel role for ARF as an important inhibitor of pulmonary tumor growth and invasion. Taken together with our previous report on tumor suppression by ARF in cutaneous squamous cell carcinoma, 53 our results argue that induction of ARF is an early response to oncogenic signaling that erects a barrier against tumor growth and invasion. ARF status may therefore have important implications for lung cancer patient prognosis and clinical management.
MATERIALS AND METHODS

Animal model
All animal experiments were approved by the Institutional Animal Care and Use Committee of the Fred Hutchinson Cancer Research Center. Arfdeficient mice 57 were backcrossed onto the NIH/Ola strain (Harlan Olac, Carshalton, UK) for 20 generations. Arf þ / À breeder mice were intercrossed and lung carcinogenesis studies performed on littermates of each genotype:
. DNA was isolated by digestion of ear tissue with proteinase K in InstaGene Matrix (Bio-Rad, Hercules, CA, USA), and each mouse was genotyped as described. 57 Mice were subjected to a single intraperitoneal injection of urethane (Sigma, St Louis, MO, USA) in a phosphate-buffered saline vehicle (1 mg/g body weight) between 21 and 28 days of age. A cohort of uninjected Arf
and Arf þ / þ (n ¼ 33) mice was included for control. Animals were euthanized by CO 2 asphyxiation at indicated time points or when moribund. Lungs were filled with fixative before excision. Tumors macroscopically visible on the pleural surface were counted, and microcalipers were used to measure tumor diameter. Normal and tumor tissues were snap-frozen in liquid nitrogen and/or fixed in neutral-buffered formalin.
Immunohistochemistry and histopathology
Formalin-fixed tissues were processed to paraffin. For analysis, 4-mm-thick sections were stained for either hematoxylin and eosin or a specific protein. Immunostaining was performed using standard methods for the following proteins: phospho-histone H3 (Ser10), phospho-histone H2A.X (Ser139), cleaved caspase-3 (Asp175), phospho-p44/42 mitogen-activated protein kinase (Thr202/Tyr204), that is, ERK1/2 (all from Cell Signaling, Danvers, MA, USA), p19
Arf (Santa Cruz Biotechnology, Santa Cruz, CA, USA), p21 (BD Biosciences, San Jose, CA, USA), Ki67 (Vector Laboratories, Burlingame, CA, USA), prosurfactant protein C (Millipore, Billerica, MA, USA), cytokeratin 8 (University of Iowa, Iowa City, IA, USA) and vimentin (Novus Biologicals, Littleton, CO, USA).
Serial sections stained with hematoxylin and eosin were analyzed and diagnosed as described. 58 To match the original stained slide, global adjustments to white balance, brightness and/or color saturation were made to copies of some photomicrographs using Adobe Photoshop. To calculate labeling indices for phospho-H3, phospho-H2A.X, Ki67 and ARF, at least 10 fields at Â 600 magnification were counted for each individual tumor, where possible (nX3 mice for each genotype and/or stage). To control for differences in staining between edge and interior fields of largediameter tumors, only immunoreactive cells within two fields of the tumor perimeter were counted for all samples.
Western blot analysis
Frozen lung tumor tissues were used to prepare nuclear and cytoplasmic protein lysates, as described. 59 Buffers were supplemented with standard protease and phosphatase inhibitors. Proteins were quantified using the Bradford assay (Bio-Rad), diluted in loading buffer, run on sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels and transferred to polyvinylidene difluoride (PVDF) membranes. Primary antibodies included cyclin D1, lamin B1, b-tubulin, total ERK1/2 and phospho-ERK1/2 (Cell Signaling), and b-actin (BioVision, Milpitas, CA, USA). Horse radish peroxidase-conjugated secondary antibodies (Santa Cruz Biotechnology) were used together with SuperSignal West detection substrate (Thermo Scientific, Rockford, IL, USA) to visualize bands. Densitometry was performed in Adobe Photoshop.
Semiquantitative PCR
Genomic DNA was isolated from frozen Arf þ / þ and Arf À / À lung adenocarcinomas and non-tumor-bearing lung tissue using the DNeasy Blood and Tissue Kit (Qiagen, Valencia, CA, USA) or Trizol (Invitrogen, Carlsbad, CA, USA) using the manufacturer's protocol. DNA concentrations were measured in triplicate using the NanoDrop 1000 spectrophotometer (Thermo Scientific). Primers for Trp53 were used to amplify equivalent amounts (20 ng) of genomic DNA over a 30 cycle PCR. Amplification reactions for a second gene, Gapdh, were performed in separate tubes, and the products run jointly on an agarose gel. The primers used were as follows: Trp53 (5 0 -CTTCTTGTAGATGTGGCGCGGACACG-3 0 ) and (5 0 -CGT GTGCTGTAGGAGCTGCTAGAGAC-3 0 ), and Gapdh (5 0 -TTCCATCCTCCAGAAA CCAG-3 0 ) and (5 0 -CCCTCGAACTAAGGGGAAAG-3 0 ).
RNA isolation and gene expression analysis
Total RNA was isolated from normal lung and lung adenocarcinomas using TRIzol reagent (Invitrogen) and subsequently purified with the RNeasy Mini Kit (Qiagen). Synthesis of cDNA was performed with SuperScript II Reverse Transcriptase using oligo(dT) or random hexamer primers (Invitrogen). The expression of Ccnd1, Bax and Mdm2 were analyzed by real-time PCR using predesigned Taqman Gene Expression Assays (Life Technologies, Carlsbad, CA, USA). Ct values were normalized to the endogenous control Gapdh and compared with the mean wild-type Ct. Fold change was analyzed between genotypes.
Kras and Trp53 mutational profiling Amplification of Kras exons 1 and 2 from cDNA (prepared as described above) was performed using primers 5 0 -AGGCCTGCTGAAAATGACTG-3 0 and 5 0 -CCAGGACCATAGGCACATCT-3 0 . The following primers were used to sequence Kras codons 12 and 13 (5 0 -CTCTATCGTAGGGTCGTAC-3 0 ), and 61 (5 0 -GACTCCTACAGGAAACAAGT-3 0 ). The Trp53 cDNA transcript spanning exons 2-11 was PCR amplified as described previously, 60 and cloned into a TOPO-TA vector (Life Technologies). Top10 competent cells were transformed, and several colonies sequenced for mutations in the Trp53 gene using an ABI 3730xl DNA Analyzer with ABI BigDye terminator cycle sequencing method (PE Applied Biosystems, Foster City, CA, USA). Sequencing results were aligned to the Trp53 transcript VEGA OTTMUST00000013379 using Sequencher 4.10.1 (Gene Codes, Ann Arbor, MI, USA).
Statistical methods
Time until development of pulmonary lesions causing death or requiring euthanasia was graphically summarized using the Kaplan-Meier method, and survival differences were analyzed for significance using the log-rank test for trend. Animals euthanized for reasons other than the presentation of pulmonary lesions were included in the analysis of overall mortality, but were considered censored observations in the second log-rank analysis. The incidence of lung tumors by 17 weeks after urethane injection was compared between genotypes; differences were analyzed for significance using the unpaired t-test. Differences in mean tumor diameter and lung mass were analyzed using the unpaired t-test. Animals that died before 20 weeks after injection were excluded from analysis of tumor size. Individual tumor diameters were graphically summarized in a scatter plot, and variations between genotypes were statistically assessed using the MannWhitney test. Incidence of benign and malignant lesions was compared between genotypes using the Fisher's exact test. Nuclear-to-cytoplasmic ratios, relative gene expression and immunoreactive cell counts were graphed and analyzed for significant differences between groups using the unpaired t-test. Values given represent mean ± s.e.m. All P-values were two-tailed, except for the statistical analysis of Ki67 cell counts, which used a one-sided P-value. P-values o0.05 were considered significant. Statistical analyses were performed in Prism (GraphPad Software, La Jolla, CA, USA).
